Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2026. “We delivered strong first quarter results based on accelerating adoption of MRD across both clinical testing and drug development.

GlobeNewsWire • May 5, 2026

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • May 5, 2026

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.

Zacks Investment Research • May 5, 2026

Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means

44,166 Common shares were sold directly for a transaction value of approximately ~$758,000, based on a weighted average sale price of $13.26 per share across April 9, 10, and 13, 2026. The disposition represented 11.95% of Julie Rubinstein's direct holdings at the time of sale, leaving her with 421,174 directly held shares following the reported transactions.

The Motley Fool • Apr 20, 2026

Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?

57,180 shares were sold for a total transaction value of approximately ~$826,000 across multiple days ending April 16, 2026. This sale represented 12.29% of Rubinstein's direct holdings at the time, reducing her directly held Common Stock to 408,160 shares.

The Motley Fool • Apr 18, 2026

Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire • Apr 15, 2026

Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On

The President and COO of Adaptive Biotechnologies Corporation reported the sale of 38,120 shares for about $554,000, based on a weighted average transaction price of $14.53 per share across April 1–2, 2026. This sale represented 7.85% of Rubinstein's direct Common Stock holdings, reducing her direct position to 447,202 shares post-transaction.

The Motley Fool • Apr 8, 2026

Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a look

81,342 shares were sold for a total value of ~$1.21 million across multiple transactions from March 6 to March 10, 2026. The sale represented 11.22% of Rubinstein's direct holdings, reducing her direct ownership to 643,471 shares post-transaction.

The Motley Fool • Mar 31, 2026

Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share Price

Francis Lo, Chief People Officer at Adaptive Biotechnologies (ADPT +0.00%), reported the sale of a combined 68,667 shares of common stock across two transactions in early March 2026, as disclosed in a pair of SEC Form 4 filings.

The Motley Fool • Mar 26, 2026